Development of Sendai virus vectors and their potential applications in gene therapy and regenerative medicine

Current Gene Therapy

Volumn 12, Issue 5, 2012, Pages 410-416

  Nakanishi, Mahito ^a   Otsu, Makoto ^b  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Gene therapy; Induced pluripotent stem cells (iPSCs); Nuclear reprogramming; Sendai virus

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; DMFCT14; LIVE VACCINE; PARAINFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

CANCER GENE THERAPY; CRITICAL LIMB ISCHEMIA; DRUG DEVELOPMENT; GENE DELIVERY SYSTEM; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; MOLECULAR THERAPY; NEOPLASM; NONHUMAN; NUCLEAR REPROGRAMMING; PLEURA MESOTHELIOMA; REGENERATIVE MEDICINE; REVIEW; SENDAI VIRUS; VIRUS GENOME;

ANIMALS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; NUCLEAR REPROGRAMMING; REGENERATIVE MEDICINE; SENDAI VIRUS;

SENDAI VIRUS;

EID: 84866982448     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312802762518     Document Type: Review

References (65)

1. Shimotohno K, Temin HM. Formation of infectious progeny virus after insertion of herpes simplex thymidine kinase gene into DNA of an avian retrovirus. Cell 1981; 26(1 Pt 1): 67-77.
2. Wei CM, Gibson M, Spear PG, Scolnick EM. Construction and isolation of a transmissible retrovirus containing the src gene of Harvey murine sarcoma virus and the thymidine kinase gene of herpes simplex virus type 1. J Virol 1981; 39(3): 935-44.
3. Berkner KL, Sharp PA. Expression of dihydrofolate reductase, and of the adjacent EIb region, in an Ad5-dihydrofolate reductase recombinant virus. Nucleic Acids Res 1984; 12(4): 1925-41.
4. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A 1987; 84(21): 7413-7.
5. Khare R, Chen CY, Weaver EA, Barry MA. Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 2011; 11(4): 241-58.
6. Tiera MJ, Shi Q, Winnik FM, Fernandes JC. Polycation-based gene therapy: current knowledge and new perspectives. Curr Gene Ther 2011; 11(4): 288-306.
7. Yi Y, Noh MJ, Lee KH. Current advances in retroviral gene therapy. Curr Gene Ther 2011; 11(3): 218-28.
8. Kumar P, Woon-Khiong C. Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications. Curr Gene Ther 2011; 11(2): 144-53.
9. Jang JH, Schaffer DV, Shea LD. Engineering biomaterial systems to enhance viral vector gene delivery. Mol Ther 2011; 19(8): 1407-15.
10. Warnock JN, Daigre C, Al-Rubeai M. Introduction to viral vectors. Methods Mol Biol 2011; 737: 1-25.
11. Lamb RA, Kolakofsky D. Paramyxoviridae: The Viruses and Their Replication. Fundamental Virology, Fourth Edition 2001: 689-724.
12. Fujita S, Eguchi A, Okabe J, et al. Sendai virus-mediated gene delivery into hepatocytes via isolated hepatic perfusion. Biol Pharm Bull 2006; 29(8): 1728-34.
13. Kuroya M, Ishida N. Newborn virus pneumonitis (type Sendai). II. The isolation of a new virus possessing hemagglutinin activity. Yokohama Med Bull 1953; 4(4): 217-33.
14. Okada Y. Sendai virus-induced cell fusion. Methods Enzymol 1993; 221: 18-41.
15. Kato K, Nakanishi M, Kaneda Y, Uchida T, Okada Y. Expression of hepatitis B virus surface antigen in adult rat liver. Cointroduction of DNA and nuclear protein by a simplified liposome method. J Biol Chem 1991; 266(6): 3361-4.
16. Uchida T, Kim J, Yamaizumi M, Miyake Y, Okada Y. Reconstitution of lipid vesicles associated with HVJ (Sendai virus) sikes. Purification and some properties of vesicles containing nontoxic fragment A of diphtheria toxin. J Cell Biol 1979; 80(1): 10-20.
17. Johnston MD. The characteristics required for a Sendai virus preparation to induce high levels of interferon in human lymphoblastoid cells. J Gen Virol 1981; 56(Pt 1): 175-84.
18. Johnston MD, Fantes KH, Finter NB. Factors influencing production of interferon by human lymphoblastoid cells. Adv Exp Med Biol 1978; 110: 61-74.
19. Shioda T, Iwasaki K, Shibuta H. Determination of the complete nucleotide sequence of the Sendai virus genome RNA and the predicted amino acid sequences of the F, HN and L proteins. Nucleic Acids Res 1986; 14(4): 1545-63.
20. Garcin D, Pelet T, Calain P, et al. A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus. EMBO J 1995; 14(24): 6087-94.
21. Schnell MJ, Mebatsion T, Conzelmann KK. Infectious rabies viruses from cloned cDNA. EMBO J 1994; 13(18): 4195-203.
22. Hasan MK, Kato A, Shioda T, et al. Creation of an infectious recombinant Sendai virus expressing the firefly luciferase gene from the 3' proximal first locus. J Gen Virol 1997; 78: 2813-20.
23. Moriya C, Shioda T, Tashiro K, et al. Large quantity production with extreme convenience of human SDF-1alpha and SDF-1beta by a Sendai virus vector. FEBS Lett 1998; 425(1): 105-11.
24. Li HO, Zhu YF, Asakawa M, et al. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol 2000; 74(14): 6564-9.
25. Yonemitsu Y, Kitson C, Ferrari S, et al. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 2000; 18(9): 970-3.
26. Masaki I, Yonemitsu Y, Komori K, et al. Recombinant Sendai virus-mediated gene transfer to vasculature: a new class of efficient gene transfer vector to the vascular system. FASEB J 2001; 15(7): 1294-6.
27. Murakami Y, Ikeda Y, Yonemitsu Y, et al. Newly-developed Sendai virus vector for retinal gene transfer: reduction of innate immune response via deletion of all envelope-related genes. J Gene Med 2008; 10(2): 165-76.
28. Goto T, Morishita M, Nishimura K, et al. Novel mucosal insulin delivery systems based on fusogenic liposomes. Pharm Res 2006; 23(2): 384-91.
29. Shibata S, Okano S, Yonemitsu Y, et al. Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene. J Immunol 2006; 177(6): 3564-76.
30. Nishimura K, Sano M, Ohtaka M, et al. Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming. J Biol Chem 2011; 286(6): 4760-71.
31. Eguchi A, Kondoh T, Kosaka H, et al. Identification and characterization of cell lines with a defect in a post-adsorption stage of Sendai virus-mediated membrane fusion. J Biol Chem 2000; 275(23): 17549-55.
32. Mizumoto K, Muroya K, Takagi T, et al. Protein factors required for in vitro transcription of Sendai virus genome. J Biochem 1995; 117(3): 527-34.
33. Hurwitz JL. Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections. Pediatr Infect Dis J 2008; 27(10 Suppl): S126-8.
34. Slobod KS, Shenep JL, Lujan-Zilbermann J, et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 2004; 22(23-24): 3182-6.
35. Bousse T, Chambers RL, Scroggs RA, Portner A, Takimoto T. Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment. Virus Res 2006; 121(1): 23-32.
36. Jones B, Zhan X, Mishin V, et al. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. Vaccine 2009; 27(12): 1848-57.
37. Yu S, Feng X, Shu T, et al. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Vaccine 2008; 26(48): 6124-31.
38. Le TV, Mironova E, Garcin D, Compans RW. Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus. PLoS One 2011; 6(4): e18780.
39. Masaki I, Yonemitsu Y, Yamashita A, et al. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 2002; 90(9): 966-73.
40. Onimaru M, Yonemitsu Y, Tanii M, et al. Fibroblast growth factor- 2 gene transfer can stimulate hepatocyte growth factor expression irrespective of hypoxia-mediated downregulation in ischemic limbs. Circ Res 2002; 91(10): 923-30.
41. Kinoh H, Inoue M, Komaru A, et al. Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies. Gene Ther 2009; 16(3): 392-403.
42. Homma M, Ouchi M. Trypsin action on the growth of Sendai virus in tissue culture cells. 3. Structural difference of Sendai viruses grown in eggs and tissue culture cells. J Virol 1973; 12(6): 1457-65.
43. Gething MJ, White JM, Waterfield MD. Purification of the fusion protein of Sendai virus: analysis of the NH2- terminal sequence generated during precursor activation. Proc Natl Acad Sci U S A 1978; 75(6): 2737-40.
44. Kido H, Yokogoshi Y, Sakai K, et al. Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J Biol Chem 1992; 267(19): 13573-9.
45. Hasegawa Y, Kinoh H, Iwadate Y, et al. Urokinase-targeted fusion by oncolytic Sendai virus eradicates orthotopic glioblastomas by pronounced synergy with interferon-beta gene. Mol Ther 2010; 18(10): 1778-86.
46. Morodomi Y, Yano T, Kinoh H, et al. BioKnife, a uPA activitydependent oncolytic Sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expression. Mol Ther 2012; 20(4): 769-77.
47. Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 1987; 51(6): 987-1000.
48. Okita K, Ichisaka T, Yamanaka S. Generation of germlinecompetent induced pluripotent stem cells. Nature 2007; 448(7151): 313-7.
49. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131(5): 861-72.
50. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126(4): 663-76.
51. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318(5858): 1917-20.
52. Jaenisch R, Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 2008; 132(4): 567-82.
53. Gonzalez F, Boue S, Izpisua Belmonte JC. Methods for making induced pluripotent stem cells: reprogramming a la carte. Nat Rev Genet 2011; 12(4): 231-42.
54. Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 2009; 85(8): 348-62.
55. Seki T, Yuasa S, Oda M, et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 2010; 7(1): 11-4.
56. Ban H, Nishishita N, Fusaki N, et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci U S A 2011; 108(34): 14234-9.
57. Carey BW, Markoulaki S, Hanna JH, et al. Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells. Cell Stem Cell 2011; 9(6): 588-98.
58. Yoshida T, Nagai Y, Maeno K, et al. Studies on the role of M protein in virus assembly using a ts mutant of HVJ (Sendai virus). Virology 1979; 92(1): 139-54.
59. Kondo T, Yoshida T, Miura N, Nakanishi M. Temperaturesensitive phenotype of a mutant Sendai virus strain is caused by its insufficient accumulation of the M protein. J Biol Chem 1993; 268(29): 21924-30.
60. Nishimura K, Segawa H, Goto T, et al. Persistent and stable gene expression by a cytoplasmic RNA replicon based on a noncytopathic variant Sendai virus. J Biol Chem 2007; 282(37): 27383-91.
61. Chan EM, Ratanasirintrawoot S, Park IH, et al. Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol 2009; 27(11): 1033-7.
62. Takayama N, Nishimura S, Nakamura S, et al. Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. J Exp Med 2010; 207(13): 2817-30.
63. Vierbuchen T, Wernig M. Direct lineage conversions: unnatural but useful? Nat Biotechnol 2011; 29(10): 892-907.
64. Qian L, Huang Y, Spencer CI, et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012; 485(7400): 593-8.
65. Song K, Nam YJ, Luo X, et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 2012; 485(7400): 599-604.